Heart shield: common diabetes drug may protect cancer patients from Chemo-Induced heart damage
NCT ID NCT06888505
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tested whether dapagliflozin, a drug used for diabetes and heart failure, can prevent heart damage caused by anthracycline chemotherapy. 90 cancer patients took either dapagliflozin or a placebo daily for four months alongside their chemo. Researchers measured heart function and blood markers to see if the drug offered protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOTOXICITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azadi Oncology Centre
Duhok, 42001, Iraq
Conditions
Explore the condition pages connected to this study.